Table 1.
Patient and tumor characteristics.
| All | UNC | MSK | MSK BCG treated | |
|---|---|---|---|---|
| n = 78 | n = 28 | n = 50 | n = 38 | |
| Age (years) | 65.0 (12.5) | 63.9 (12.1) | 65.6 (12.7) | 66.8 (11.4) |
| Male sex | 59 (75.6%) | 22 (78.6%) | 37 (74.0%) | 29 (76.3%) |
| Stage and gradea | ||||
| T1 high-grade | 35 (46.1%) | 18 (64.3%) | 17 (34.0%) | 14 (36.8%) |
| Ta high-grade | 25 (32.0%) | 0 (0.0%) | 25 (50.0%) | 23 (60.5%) |
| Ta low-grade | 18 (21.1%) | 10 (35.7%) | 8 (16.0%) | 1 (2.6%) |
| Carcinoma in situ (CIS) | 22 (28.2%) | 8 (28.5%) | 14 (28.0%) | 14 (36.8%) |
| Tumor cellularitya | ||||
| 0–40 | 33 (43.4%) | 13 (46.4%) | 18 (36.0%) | 17 (44.7%) |
| 50–90 | 43 (56.7%) | 11 (39.3%) | 32 (64.0%) | 21 (55.3%) |
| UROMOL subclass | ||||
| 1/ Luminal | 26 (33.3%) | 7 (25.0%) | 19 (38.0%) | 10 (26.3%) |
| 2/ CIS-like | 28 (35.9%) | 8 (27.6%) | 20 (40.0%) | 17 (44.7%) |
| 3/ Early basal-like | 24 (30.85%) | 13 (46.4%) | 11 (22.0%) | 11 (30.0%) |
| Immune scoreb | ||||
| Low | 20 (25.6%) | 6 (21.4%) | 14 (28.0%) | 11 (30.0%) |
| Medium | 20 (25.6%) | 5 (17.9%) | 15 (30.0%) | 8 (21.0%) |
| High | 38 (48.7%) | 17 (60.7%) | 21 (42.0%) | 19 (50.0%) |
| Treatment | ||||
| BCG | 38 (76%) | 38 (100%) | ||
| Mitomycin | 5 (10%) | 0 | ||
| TURBT only | 6 (12%) | 0 | ||
| Cystectomy | 1 (2%) | 0 | ||
| Tumor size ≥3 cm | 26 (52%) | 18 (47.4%) | ||
| Multiple tumors | 19 (38%) | 18 (47.4%) | ||
Note: Data are presented as mean (SD) or n (%).
Abbreviations: CIS, carcinoma in situ; MSK, Memorial Sloan Kettering Cancer Center; rankBCG, bacillus Calmette-Guérin; SD, standard deviation; TURBT, transurethral resection of the bladder tumor; UNC, University of North Carolina.
aMissing values omitted.
bGrouped into tertiles based on score.